Search

Displaying results 2411 - 2420 of 7540 in total
  1. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.

  2. Drug

    Dopamine

    go.drugbank.com/drugs/DB00988
    ApprovedInvestigational

    It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement.

  3. Drug

    Azlocillin

    go.drugbank.com/drugs/DB01061
    Approved

    Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.

  4. Drug

    Human cytomegalovirus immune globulin

    go.drugbank.com/drugs/DB13886
    ApprovedInvestigational

    Cytomegalovirus, a member of the herpes virus family, is ubiquitous the human population, leading to infections which are followed by life-long dormancy in the host with occasional reactivations and recurrent … Molecular mechanisms have been identified by which show that CMVs interfere with the host immune system. Finally, however, the infection is normally controlled by the host's immune response.

  5. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults … [A241030] Evidence increasingly points to a role for the complement system in TMA.

  6. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

    Categories: Histamine H1 Antagonists, Non-Sedating
  7. Drug

    Varicella zoster vaccine (live/attenuated)

    go.drugbank.com/drugs/DB10318
    ApprovedInvestigational

    This is a significant improvement over its predecessor, Zostavax, which reduces the risk of shingles by only 51% and the risk of post-herpetic neuralgia by 67% [A31349]. … Other complications also include bacterial infection, spread of the shingles rash to the eye (herpes zoster ophthalmicus) or ear, nerve palsies, or spread of VZV to non-immune persons via contact with

  8. Drug

    Botulinum toxin type A

    go.drugbank.com/drugs/DB00083
    ApprovedInvestigational

    In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.

  9. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. … Schizophrenia is characterized by positive symptoms such as delusions, hallucinations, thought disorders, and catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Icaridin

    go.drugbank.com/drugs/DB14074
    Investigational

    Icaridin was synthesized by Bayer in the 1980s based on molecular modeling [L4595]. … It is considered to be the first choice of repellent by the Public Health Agency of Canada’s Canadian Advisory Committee on Tropical Medicine and Travel for travelers six months to 12 years of age [A39203